亞太生物製劑藥物研發市場：按製造商、類型和國家分類的分析和預測（2025-2035 年）

亞太地區生物製劑藥物研發市場預計將從2024年的48.7億美元成長到2035年的167.1億美元，預測期（2025-2035年）年複合成長率為 11.90%。

亞太地區的生物製劑研發市場正經歷顯著成長，這主要得益於慢性病和罕見疾病的日益增多以及精準醫療趨勢的加速發展。單株抗體、重組蛋白和新一代療法等生物製劑因其優於傳統小分子藥物的療效和更高的特異性，在全部區域日益普及。中國、日本、韓國、印度和澳洲等國家不斷擴大的產學合作、政府主導的研發計劃以及不斷完善的法規結構，都為該地區的生物製劑發展做出了貢獻。

由於技術進步，亞太地區的藥物研發格局迅速改變。人工智慧驅動的標靶發現、高通量篩檢、多體學平台和先進抗體設計工具的整合，增強該地區的創新能力並提高早期研發效率。然而，研究基礎設施的異質性、監管成熟度的差異、高昂的研發成本以及部分國家有限的生物製藥生產能力等障礙，仍限制研發進程。但不斷成長的投資、對區域性合約研究組織（CRO）和合約研發生產機構（CDMO）日益成長的外包需求，以及對個性化和基於機制治療方法的快速成長的需求，正使該地區成為生物製藥研發和未來治療創新領域快速發展的中心。

市場概覽

罕見疾病和慢性病的日益增多、對個人化治療需求的成長以及亞太地區醫療基礎設施的不斷完善，共同推動了該地區生物製劑藥物研發市場的顯著成長。在政府資助的研究計劃、產學合作以及不斷壯大的專業合約研究組織（CRO）和合約研發生產組織（CDMO）網路的推動下，中國、日本、韓國、印度和澳洲等國家正成為生物製劑研發的重要中心。與傳統小分子藥物相比，生物製劑，包括單株抗體、重組蛋白、多特異性抗體和基因療法等新一代療法，因其更高的特異性、有效性和安全性而日益受到青睞。

技術創新加速該地區的藥物研發進程。先進的抗體工程、多體學整合、高通量篩檢以及人工智慧驅動的目標發現技術提高早期研究的效率和成功率。此外，數位技術和真實世界資料的應用推動生物標記主導的藥物研發和精準醫療策略的發展。

儘管取得了這些進展，但仍存在許多障礙，包括研發成本不斷上漲、生產流程複雜以及監管成熟度和合格人才供應方面的區域差異。然而，外包模式的擴展、公共和私營部門投資的增加以及對個人化醫療日益成長的關注，已使亞太地區成為生物製劑藥物研發的快速發展中心，並有望在未來十年為全球治療創新做出重大貢獻。

市場區隔:

細分 1：依生產類型

• 內部生產
• 外包委託製造

細分 2：依類型

• 單株抗體
• 重組蛋白
• 其他生物製劑

細分3：依地區

• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 其他

本報告檢視了亞太地區的生物製劑藥物研發市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 生物製劑藥物研發市場：產業展望

• 市場概覽
• 主要市場趨勢
  • 雙特異性和多特異性抗體研發進展
  • 加強夥伴關係與合作
  • 對外包服務的需求不斷成長
• 監管狀態
  • 亞太地區
• 供應鏈分析
  • 供應鍊及其風險
• 專利分析
  • 專利申請趨勢（依國家）
  • 專利申請趨勢（依年份）
• 市場動態
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 生物製劑藥物研發市場（依地區）

• 亞太地區
  • 區域概覽
  • 市場成長促進因素
  • 市場問題
  • 市場規模及預測

第3章 競爭基準化分析與公司概況

• 公司簡介
  • Astellas Pharma Inc.
  • GenScript Biotech Corporation
  • WuXi Biologics（Cayman）Inc.

第4章 調查方法

This report can be delivered in 2 working days.

Introduction to Asia-Pacific Biologics Drug Discovery Market

The Asia-Pacific biologics drug discovery market is projected to reach $16.71 billion by 2035 from $4.87 billion in 2024, growing at a CAGR of 11.90% during the forecast period 2025-2035. As the region deals with an increasing number of chronic and rare diseases as well as an accelerating trend toward precision-focused medicines, the APAC biologics drug development market is gaining significant traction. Because they provide better therapeutic outcomes and greater specificity than conventional small drugs, biologics-such as monoclonal antibodies, recombinant proteins, and next-generation modalities-are becoming more and more popular throughout APAC. Growing academic-industry collaborations, government-led R&D projects, and changing regulatory frameworks in nations like China, Japan, South Korea, India, and Australia all contribute to the region's advancement.

APAC's discovery landscape is rapidly changing due to technological improvements. The region's ability for innovation is being strengthened and early-stage efficiency is being improved through the integration of AI-driven target identification, high-throughput screening, multi-omics platforms, and sophisticated antibody-engineering tools. Despite this expansion, obstacles like uneven research infrastructure, inconsistent regulatory maturity, high development costs, and restricted biologics manufacturing capacity in some countries continue to influence the rate of advancement. Nevertheless, APAC is becoming a rapidly developing center for biologics drug development and future therapeutic innovation due to growing investments, increasing outsourcing to regional CROs and CDMOs, and accelerated demand for individualized and mechanism-based treatments.

Market Introduction

The growing prevalence of uncommon and chronic diseases, the growing need for tailored treatments, and the development of the region's healthcare infrastructure are all contributing factors to the APAC biologics drug discovery market's notable expansion. With the help of government-funded research projects, industry-academia partnerships, and an expanding network of specialized CROs and CDMOs, nations like China, Japan, South Korea, India, and Australia are becoming important centers for biologics R&D. Because they are more specific, effective, and safe than traditional small drugs, biologics-which include monoclonal antibodies, recombinant proteins, and next-generation modalities like multispecific antibodies and gene therapies-are becoming more and more popular.

The region's discovery pipelines are being accelerated by technological advancements. Advanced antibody engineering, multi-omics integration, high-throughput screening, and AI-driven target discovery are increasing the effectiveness and success rates of early-stage research. Furthermore, the use of digital technologies and real-world data is improving biomarker-driven drug development and precision medicine strategies.

Notwithstanding these developments, there are still many obstacles to overcome, including expensive research costs, intricate manufacturing specifications, and differences in regulatory maturity and qualified personnel within APAC markets. However, growing outsourcing models, rising public and private sector investment, and an increasing emphasis on personalized medicine are positioning APAC as a rapidly developing hub for biologics drug discovery, with the potential to make a substantial contribution to global therapeutic innovation over the next ten years.

Market Segmentation:

Segmentation 1: By Manufacturing Type

• In-House Manufacturing
• Outsourced Manufacturing

Segmentation 2: By Type

• Monoclonal Antibodies
• Recombinant Proteins
• Other Biologics

Segmentation 3: By Region

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

APAC Biologics Drug Discovery Market Trends, Drivers and Challenges

Market Trends

• Strong adoption of monoclonal antibodies, recombinant proteins, and next-generation biologics such as gene and cell therapies.
• Increasing use of AI, machine learning, and computational tools for target identification and lead optimization.
• Expansion of public-private partnerships and collaborations between pharma, biotech, and academic institutions.
• Growing outsourcing to regional CROs and CDMOs for specialized biologics R&D and manufacturing.
• Rising focus on precision medicine and biomarker-driven approaches across therapeutic areas like oncology, immunology, and neurology.

Market Growth Drivers

• Rising prevalence of chronic, autoimmune, and rare diseases across APAC, fueling demand for innovative biologics.
• Government-backed R&D funding and supportive regulatory frameworks enhancing research capabilities.
• Technological advancements, including high-throughput screening, multi-omics analysis, and antibody engineering.
• Increasing investments from pharma, biotech, and venture capital supporting early-stage discovery.
• Adoption of digital tools and real-world evidence to optimize drug development and clinical success rates.

Market Challenges

• High development and manufacturing costs for biologics, particularly for advanced modalities.
• Regulatory variability across APAC countries creating delays and complexity in approvals.
• Limited skilled talent in biologics discovery, CMC, and regulatory sciences in certain markets.
• Infrastructure disparities, including availability of specialized labs and biologics manufacturing facilities.
• Supply-chain vulnerabilities for APIs and reliance on regional CDMOs, leading to potential delays and cost pressures.

How can this report add value to an organization?

Product/Innovation Strategy: The APAC biologics drug discovery market has been extensively segmented based on various categories, such as manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments.

Competitive Strategy: The APAC biologics drug discovery market has numerous established players with product portfolios. Key players in the APAC biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Astellas Pharma Inc.
• GenScript Biotech Corporation
• WuXi Biologics (Cayman) Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Biologics Drug Discovery Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Key Market Trends
  • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
  • 1.2.2 Rising Partnerships and Collaborations
  • 1.2.3 Rising Demand for Outsourcing Services
• 1.3 Regulatory Landscape
  • 1.3.1 Asia-Pacific
    • 1.3.1.1 China
    • 1.3.1.2 Japan
• 1.4 Supply Chain Analysis
  • 1.4.1 Supply Chain and Risks within the Supply Chain
• 1.5 Patent Analysis
  • 1.5.1 Patent Filing Trend (by Country)
  • 1.5.2 Patent Filing Trend (by Year)
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
    • 1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
  • 1.6.3 Market Opportunities
    • 1.6.3.1 AI Integration in Biologics Discovery

2 Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

• 2.1 Asia-Pacific
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Market Sizing and Forecast
    • 2.1.4.1 Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
    • 2.1.4.2 Asia-Pacific Biologics Drug Discovery Market, by Type
    • 2.1.4.3 Asia-Pacific Biologics Drug Discovery Market, by Country
      • 2.1.4.3.1 China
        • 2.1.4.3.1.1 Country Overview
        • 2.1.4.3.1.2 Driving Factors for Market Growth
        • 2.1.4.3.1.3 Factors Challenging the Market
        • 2.1.4.3.1.4 Market Sizing and Forecast
        • 2.1.4.3.1.4.1 China Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.1.4.2 China Biologics Drug Discovery Market, by Type
      • 2.1.4.3.2 Japan
        • 2.1.4.3.2.1 Country Overview
        • 2.1.4.3.2.2 Driving Factors for Market Growth
        • 2.1.4.3.2.3 Factors Challenging the Market
        • 2.1.4.3.2.4 Market Sizing and Forecast
        • 2.1.4.3.2.4.1 Japan Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.2.4.2 Japan Biologics Drug Discovery Market, by Type
      • 2.1.4.3.3 India
        • 2.1.4.3.3.1 Country Overview
        • 2.1.4.3.3.2 Driving Factors for Market Growth
        • 2.1.4.3.3.3 Factors Challenging the Market
        • 2.1.4.3.3.4 Market Sizing and Forecast
        • 2.1.4.3.3.4.1 India Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.3.4.2 India Biologics Drug Discovery Market, by Type
      • 2.1.4.3.4 South Korea
        • 2.1.4.3.4.1 Country Overview
        • 2.1.4.3.4.2 Driving Factors for Market Growth
        • 2.1.4.3.4.3 Factors Challenging the Market
        • 2.1.4.3.4.4 Market Sizing and Forecast
        • 2.1.4.3.4.4.1 South Korea Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.4.4.2 South Korea Biologics Drug Discovery Market, by Type
      • 2.1.4.3.5 Australia
        • 2.1.4.3.5.1 Country Overview
        • 2.1.4.3.5.2 Driving Factors for Market Growth
        • 2.1.4.3.5.3 Factors Challenging the Market
        • 2.1.4.3.5.4 Market Sizing and Forecast
        • 2.1.4.3.5.4.1 Australia Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.5.4.2 Australia Biologics Drug Discovery Market, by Type
      • 2.1.4.3.6 Rest-of-Asia-Pacific
        • 2.1.4.3.6.1 Country Overview
        • 2.1.4.3.6.2 Driving Factors for Market Growth
        • 2.1.4.3.6.3 Factors Challenging the Market
        • 2.1.4.3.6.4 Market Sizing and Forecast
        • 2.1.4.3.6.4.1 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
        • 2.1.4.3.6.4.2 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Type

3 Competitive Benchmarking and Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Astellas Pharma Inc.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products/Product Portfolio
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers
    • 3.1.1.5 Key Personal
    • 3.1.1.6 Analyst View
  • 3.1.2 GenScript Biotech Corporation
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products/Product Portfolio
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Target Customers
    • 3.1.2.5 Key Personal
    • 3.1.2.6 Analyst View
  • 3.1.3 WuXi Biologics (Cayman) Inc.
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products/Product Portfolio
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Target Customers
    • 3.1.3.5 Key Personal
    • 3.1.3.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figure

• Figure 1: Asia-Pacific Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
• Figure 2: Asia-Pacific Biologics Drug Discovery Market, 2024 and 2035
• Figure 3: Biologics Drug Discovery Market, $Billion, 2025 and 2035
• Figure 4: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
• Figure 5: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
• Figure 6: Number of Patents Filed (by Country), January 2021 to 12th September 2025
• Figure 7: Number of Patents Filed (by Year), January 2021 to 12th September 2025
• Figure 8: Incidence of Cancer (by Region), 2020-2040
• Figure 9: Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 10: China Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 11: Japan Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 12: India Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 13: South Korea Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 14: Australia Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 15: Rest-of-Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Biologics Drug Discovery Market, Key Market Trends
• Table 3: Key Partnerships in the Biologics Drug Discovery Market
• Table 4: Market Dynamics
• Table 5: Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
• Table 6: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 7: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 8: Asia-Pacific Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
• Table 9: China Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 10: China Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 11: Japan Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 12: Japan Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 13: India Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 14: India Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 15: South Korea Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 16: South Korea Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 17: Australia Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 18: Australia Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
• Table 19: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
• Table 20: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035